BCLI News Alert Brainstorm Cell Ther (BCLI) 5.00 01/06/2015

New Post Public Reply Private Reply Replies (0) Message Board

Jan 6, 2015 at 6:24 PM

Brainstorm Cell Ther (BCLI) 5.00 $BCLI

Brainstorm Takes Major Leap Forward In Battle Vs. ALS
Jason Napodano, CFA - Seeking Alpha - Tue Jan 06, 9:51AM CST
By Jason Napodano On Monday, January 5, 2015 Brainstorm Cell Therapeutics (NASDAQ: BCLI ) announced final results from the Phase 2a clinical trial of NurOwn as a treatment for patients suffering from amyotrophic lateral sclerosis (ALS). Below we...
BCLI: 5.00 (-0.75)

BrainStorm CEO to Present at Two Upcoming Investor Conferences
PR Newswire - Tue Jan 06, 6:05AM CST
BrainStorm Cell Therapeutics Inc. (NASDAQ:BCLI), a leading developer of adult stem cell technologies for neurodegenerative diseases, today announced that Tony Fiorino, MD, PhD, Chief Executive Officer, will be presenting at two upcoming investor conferences.
BCLI: 5.00 (-0.75)

A Look At BrainStorm Cell Therapeutics' ALS Phase IIa Results
Wall Street Titan - at Seeking Alpha - Mon Jan 05, 2:48PM CST

ATHX: 2.00 (+0.18), BCLI: 5.00 (-0.75)

15 Biotech Names For 2015
Jason Napodano, CFA - at Seeking Alpha - Mon Jan 05, 1:37PM CST

NBIX: 20.53 (-0.87), LPCN: 5.07 (-0.19), EPRS: 5.96 (+0.11), DEPO: 15.80 (-0.23), ASPX: 50.78 (-2.21), BCLI: 5.00 (-0.75), CUR: 3.35 (+0.37)

Midday Gainers / Losers
Seeking Alpha - at Seeking Alpha - Mon Jan 05, 11:48AM CST

SD: 1.41 (-0.12), XENT: 20.23 (-0.50), WLL: 29.40 (-0.34), BTE: 14.21 (-0.50), BOTA: 2.65 (-0.20), CNAT: 10.63 (+0.57), WG: 5.40 (+0.01), SN: 8.39 (+0.05), LPI: 8.42 (-0.95), EROC: 2.16 (-0.04), BCLI: 5.00 (-0.75), NDRM: 15.45 (+1.80), SMLR: 2.69 (+0.34), QURE: 17.23 (+0.07), SFY: 3.23 (+0.07), ANTH: 2.20 (-0.07), PLX: 2.02 (-0.15), APRI: 1.31 (-0.03), STXS: 1.70 (-0.18), GST: 2.14 (-0.14)

Investors bag some profits on Brainstorm
Seeking Alpha - at Seeking Alpha - Mon Jan 05, 10:56AM CST

BCLI: 5.00 (-0.75)

Brainstorm Stem-Cell Therapy Continues to Show Treatment Effect in ALS Patients
at The Street - Mon Jan 05, 9:52AM CST
Final results from a mid-stage study of Brainstorm's NurOwn therapy show a slowing of disease progression in some ALS patients.
BCLI: 5.00 (-0.75)

Premarket Gainers / Losers
Seeking Alpha - at Seeking Alpha - Mon Jan 05, 8:10AM CST

CERS: 5.78 (-0.79), E: 32.08 (+0.12), SSL: 34.64 (-0.36), CNAT: 10.63 (+0.57), SDRL: 10.48 (-0.33), NBG: 1.58 (-0.08), BCLI: 5.00 (-0.75), URZ: 1.20 (+0.02), PBR: 6.02 (-0.05), ISIS: 65.44 (-2.73), KITE: 71.45 (+1.70), PLX: 2.02 (-0.15), CEMP: 23.15 (-1.40), STXS: 1.70 (-0.18)

BrainStorm Announces Final Analysis of Phase 2a ALS Study Showing Nearly All Subjects Experienced Clinical Benefit from NurOwn(TM)
PR Newswire - Mon Jan 05, 7:20AM CST
BrainStorm Cell Therapeutics Inc. (NASDAQ:BCLI), a leading developer of adult stem cell technologies for neurodegenerative diseases, today announced positive final results from its phase 2a clinical trial of NurOwn(TM) in amyotrophic lateral sclerosis (ALS) patients, which enrolled 14 subjects at Hadassah Medical Center in Jerusalem.
BCLI: 5.00 (-0.75)

Stocks in Whipsaw to Start 2015 as Weak Manufacturing Blunts Optimism
at The Street - Fri Jan 02, 3:20PM CST
Wall Street will likely excuse the bumpy start to the year as traders focus on a busy week ahead.
MU: 32.87 (-0.91), PSMT: 89.85 (+0.15), MON: 116.25 (-1.06), SYNA: 60.43 (-3.29), GBX: 49.31 (-2.76), WYNN: 141.31 (-3.08), LVS: 53.36 (-1.40), FDO: 78.67 (+0.01), HNR: 0.90 (-0.07), MGM: 19.66 (-0.78), BCLI: 5.00 (-0.75), RAD: 7.71 (+0.19), BLDP: 1.74 (-0.04), AYI: 134.81 (-1.71), AA: 15.07 (+0.11), BBBY: 75.42 (-0.43), SONC: 27.09 (+0.05)

Rite Aid and Petrobras are big market movers
AP - Fri Jan 02, 3:11PM CST
NEW YORK (AP) — Stocks that moved substantially or traded heavily Friday on the New York Stock Exchange and the Nasdaq Stock Market:
BLDP: 1.74 (-0.04), BLD.TO: 2.04 (-0.06), GNTX: 17.16 (-0.35), HNR: 0.90 (-0.07), BCLI: 5.00 (-0.75), RAD: 7.71 (+0.19)

Stocks Yo-Yo as U.S. Manufacturing Activity Hits Six-Month Low
at The Street - Fri Jan 02, 1:39PM CST
Indications of weakness in manufacturing serve to reverse the S&P 500 which had jumped at the open.
BLDP: 1.74 (-0.04), SYNA: 60.43 (-3.29), WYNN: 141.31 (-3.08), LVS: 53.36 (-1.40), MGM: 19.66 (-0.78), HNR: 0.90 (-0.07), BCLI: 5.00 (-0.75), RAD: 7.71 (+0.19)

Stocks Turn Negative as U.S. Manufacturing Slides to Six-Month Low
at The Street - Fri Jan 02, 9:49AM CST
The stock market rallied in the first trading day of the year as positive sentiment carried over into 2015.
BLDP: 1.74 (-0.04), BBBY: 75.42 (-0.43), BCLI: 5.00 (-0.75), RAD: 7.71 (+0.19)

Brainstorm Cell Therapeutics (BCLI) Stock Hits One-Year High Today
at The Street - Fri Jan 02, 8:53AM CST
Shares of Brainstorm Cell Therapeutics (BCLI) soared more than 75% to a 52-week high of $8.47 on Friday ahead of the biotech company's data release on Monday.
BCLI: 5.00 (-0.75)

Premarket Gainers / Losers as of 9:10 am
Seeking Alpha - at Seeking Alpha - Fri Jan 02, 8:14AM CST

KOOL: 1.00 (-0.02), BLDP: 1.74 (-0.04), PBR: 6.02 (-0.05), LNCO: 11.31 (+0.09), KITE: 71.45 (+1.70), NRX: 9.28 (-0.87), LINE: 11.22 (+0.07), PWRD: 19.10 (+0.11), BCLI: 5.00 (-0.75), CUR: 3.35 (+0.37)

Brainstorm up big premarket on NurOwn results in ALS
Seeking Alpha - at Seeking Alpha - Fri Jan 02, 7:27AM CST

BCLI: 5.00 (-0.75)

Stock Futures Point to Positive Open in First Session of 2015
at The Street - Fri Jan 02, 7:12AM CST
Stock futures look to kick off 2015 with gusto on the first trading day of the year.
BBBY: 75.42 (-0.43), LINE: 11.22 (+0.07), BCLI: 5.00 (-0.75)

Happy New 'Investing' Year: Complementary Reports on Daily Journal, Trina Solar, Cytokinetics, BrainStorm, and Resolute
PR Newswire - Fri Jan 02, 7:10AM CST
Moments ago, Analysts Review released new research updates concerning several important developing situations including Daily Journal (NASDAQ: DJCO), Trina Solar (NYSE: TSL), Cytokinetics (NASDAQ: CYTK), BrainStorm (NASDAQ: BCLI), and Resolute (NYSE: REN). Analysts Review provides a single unified platform for investors' to hear about what matters - proudly employing registered CFA® research staff and rigorous compliance procedures. The full research reports are being made available to the public for informational purposes only.
CYTK: 7.22 (-0.45), REN: 1.03 (-0.06), TSL: 8.79 (-0.30), DJCO: 229.98 (-0.20), BCLI: 5.00 (-0.75)

Newer

Older

Scroll down for more posts ▼

Top 10 Most Recent News Articles

Intus Bio Secures $2.7M for Colorectal Cancer Test

Pioneering Efforts in Early-Onset Colorectal Cancer Detection The battlefield of colorectal cancer prevention just got a serious upgrade with Intus Bio grabbing a $2.7 million award. This ain't just pocket change—it's a shot at rewriting the script on how we approach early-onset colorectal cancer, the pesky number one cancer gnawing at the under-50 crowd. Partnering...

DCM Services Teams with AKUVO to Boost Estate Recoveries

Revolutionizing Estate Recovery Practices Here's the scoop: DCM Services (DCMS), that big shot in estate account resolution, is hooking up with AKUVO to shake up how credit unions handle estate recoveries. This alliance is a clear nod to modernizing a process stuck in the past. Let’s face it, handling decedent and probate accounts is no cakewalk, and traditional methods...

QuickFi Nabs Top Finovate Award for Fourth Time

An Unstoppable Force in Fintech Well, if QuickFi hasn't made a name for itself in fintech, then folks, I don't know what to tell you. This year, they’ve snagged yet another prestigious Finovate Award—this time for Best SMB/SME Banking Solution. That's not their first rodeo either; it’s the fourth time they’ve walked away winners. It's almost like they're...

2026 Buy-Side Index Reveals State Market Variance

Toss out your one-size-fits-all real estate predictions; the Q2 2026 Buy-Side Index just unveiled some real whoppers about the housing market. What we're seeing isn't your typical year-over-year growth across the board. Nope, we're seeing splits as sharp as a knife between states. Some places are shooting up in price, while others seem to be stuck in mud. Price Surges and...

NYSE Reflects on 9/11: Honoring Lives and Legacy

A Somber Day at NYSE: Reflecting on 9/11 September 11th grips the heart of NYSE every year, but this year's 25th-anniversary powerfully reverberates through its hallowed halls. The hustle of the trading floor halts for a moment at 9:20 AM ET, paying homage to those lost in the harrowing attacks. I've seen the markets flap in the wind of countless crises, but nothing's...

Sustainability Investments: $17 Trillion Wager Faces Divergence

Sustainability Investments: A Tale of Contrasts In the world of sustainability, a staggering $17 trillion has been poured into technologies over the past decade. That’s no chump change. But what do we have to show for it? According to Bain & Company’s latest report, this massive financial injection hasn’t exactly hit a home run. Progress, much like the stock market...

Oil Markets Shift Focus: Pipelines Trump Drilling

Decoupling Oil Price and Production Response This oil market isn’t your usual rodeo. With Brent flirting with $100, it’s a seismic shift that’s not yielding new drills but redirecting capital to the existing infrastructure landscape. Ask yourself why we're not seeing the usual cavalry charge of new rigs. It’s simple: Pipeline mileage and producing wells have...

Lick the Plate Hits 2,000 Shows with Clown Band

They say good things come in bizarre packages, and that's exactly the case as David Boylan's Lick the Plate zany celebration marks 15 years on air with its 2,000th episode. If you think of radio as a predictable endeavor, well, you're not tuned into Lick the Plate. A Milepost Draped in Multicolored Fabrics When you're browsing through colorful avenues of radio fame, it's...

Fermi's Founder Pushes for Board Overhaul: What's Next?

Fermi's Roller Coaster: A Founder’s Stand Seems like Fermi Inc. is on a wild ride through the business landscape, and it's giving shareholders more whiplash than satisfaction these days. Toby Neugebauer, co-founder of Fermi and the loudest voice in the room, is feeling like his company is facing some serious turbulence and seems determined not to sit idly by as it hits...

Supply Maverick Simplifies Global Shipping Processes

Paving the Way for Seamless International Shipping Supply Maverick's got a new mantra, folks: simplicity. They're slicing through the mess of international shipping and bringing some much-needed clarity for customers in Canada, Australia, and New Zealand. It’s about time someone shook up the logistics playbook. The Nuts and Bolts of the New Shipping System Imagine being...